322 related articles for article (PubMed ID: 25576066)
1. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
Fujinaga S; Sakuraya K; Yamada A; Urushihara Y; Ohtomo Y; Shimizu T
Pediatr Nephrol; 2015 Apr; 30(4):687-91. PubMed ID: 25576066
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.
Fujinaga S; Someya T; Watanabe T; Ito A; Ohtomo Y; Shimizu T; Kaneko K
Eur J Pediatr; 2013 Apr; 172(4):513-8. PubMed ID: 23271494
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center.
Fujinaga S; Ohtomo Y; Hirano D; Nishizaki N; Someya T; Ohtsuka Y; Kaneko K; Shimizu T
Clin Nephrol; 2009 Oct; 72(4):268-73. PubMed ID: 19825332
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
[TBL] [Abstract][Full Text] [Related]
5. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
6. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome.
Fujinaga S; Ohtomo Y; Umino D; Takemoto M; Shimizu T; Yamashiro Y; Kaneko K
Pediatr Nephrol; 2007 Jan; 22(1):71-6. PubMed ID: 17086405
[TBL] [Abstract][Full Text] [Related]
7. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
8. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
[TBL] [Abstract][Full Text] [Related]
9. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
Gellermann J; Ehrich JH; Querfeld U
Nephrol Dial Transplant; 2012 May; 27(5):1970-8. PubMed ID: 21976740
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome.
Sinha A; Gupta A; Kalaivani M; Hari P; Dinda AK; Bagga A
Kidney Int; 2017 Jul; 92(1):248-257. PubMed ID: 28318625
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
Mendizábal S; Zamora I; Berbel O; Sanahuja MJ; Fuentes J; Simon J
Pediatr Nephrol; 2005 Jul; 20(7):914-9. PubMed ID: 15891923
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome.
Bagga A; Hari P; Moudgil A; Jordan SC
Am J Kidney Dis; 2003 Dec; 42(6):1114-20. PubMed ID: 14655181
[TBL] [Abstract][Full Text] [Related]
13. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children.
Ulinski T; Dubourg L; Saïd MH; Parchoux B; Ranchin B; Cochat P
Pediatr Nephrol; 2005 Apr; 20(4):482-5. PubMed ID: 15719253
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome.
Okada M; Sugimoto K; Yagi K; Yanagida H; Tabata N; Takemura T
Pediatr Int; 2007 Dec; 49(6):933-7. PubMed ID: 18045300
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.
Gellermann J; Weber L; Pape L; Tönshoff B; Hoyer P; Querfeld U;
J Am Soc Nephrol; 2013 Oct; 24(10):1689-97. PubMed ID: 23813218
[TBL] [Abstract][Full Text] [Related]
16. [Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome].
Geng HY; Ji LN; Chen CY; Tu J; Li HR; Bao R; Lin Y
Zhonghua Er Ke Za Zhi; 2018 Sep; 56(9):651-656. PubMed ID: 30180402
[No Abstract] [Full Text] [Related]
17. Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome in children.
Nickavar A; Safarzadeh AE; Sotoudeh K; Otukesh H; Hooman N
Iran J Kidney Dis; 2012 Sep; 6(5):346-9. PubMed ID: 22976259
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
Fujinaga S; Nishino T; Umeda C; Tomii Y; Watanabe Y; Sakuraya K
Pediatr Nephrol; 2019 Feb; 34(2):353-357. PubMed ID: 30426219
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
